Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00605-9
Affiliations:
17
Authors:
27
Go to article
Institutions Authors Share
CHRU de Besançon, France
3.833333
 0.20
Unité Mixte de Recherche RIGHT, France
2.833333
 0.15
Centre d'Investigation Clinique de Besançon, France
2.333333
 0.12
Centre Antoine-Lacassagne (CAL), France
1.000000
 0.05
Institut Hospitalier Franco-Britannique (IHFB), France
1.000000
 0.05
Hôpital Privé Jean Mermoz, France
1.000000
 0.05
CHU de Reims, France
1.000000
 0.05
Centre Léon Bérard (CLB), France
1.000000
 0.05
CHU de Poitiers, France
1.000000
 0.05
Centre Georges-François Leclerc (CGFL), France
1.000000
 0.05
Boehringer Ingelheim International GmbH, Germany
1.000000
 0.05
Boehringer Ingelheim - France, France
1.000000
 0.05
Institut de Recherche Saint-Louis (IRSL), France
0.500000
 0.03
Hôpital Saint-Louis, France
0.500000
 0.03
Interested in Oncology and Carcinogenesis?